Analog Devices, Inc. (ADI) has achieved a milestone with the announcement of US Food and Drug Administration (FDA) 510(k) clearance and the commercial release of its Sensinel™ Cardiopulmonary Management (CPM) System. 

This compact wearable device represents a breakthrough in chronic disease management, particularly for conditions like heart failure, and marks the company's first FDA clearance in its 59-year history.

Patrick O'Doherty, Senior Vice President of Digital Healthcare at ADI, expressed the company's commitment to innovation and improving patient care with the Sensinel CPM System. "By combining our wearable vital signs sensing and signal processing technology with cardiologist-inspired algorithms, we developed the Sensinel CPM System," said O'Doherty. "This innovative service-based product has the potential to open up several billion dollars of green-field market opportunity for ADI while improving patient care, streamlining clinician workflows, and reducing healthcare cost."

Heart failure affects over 6 million Americans today, with projections estimating a rise to nearly 8 million by 2030. The economic burden of heart failure currently stands at approximately USD 30 billion annually, expected to increase to almost USD 70 billion by 2030. A significant portion of these costs stems from hospitalization, making early detection and intervention crucial for preventing costly admissions.

The Sensinel CPM System offers a non-invasive solution for managing cardiopulmonary diseases, providing care teams with precise and remote monitoring capabilities. Patients simply apply the Sensinel CPM Wearable for three to five minutes in a home care setting, allowing the device to capture vital data about their cardiopulmonary health. This data is then securely transmitted to ADI's cloud platform for analysis using intelligent algorithms.

Dr. Sean Pinney, Chief of Cardiology at Mount Sinai Morningside in New York City, emphasized the importance of early detection in preventing heart failure hospitalizations. "ADI's Sensinel CPM System is a highly accurate, reproducible, and reliable solution to help improve predictive care," said Dr. Pinney.

Dr. Venu Gopinathan, ADI Fellow and Managing Director of Medical Products, highlighted the system's ability to provide clinicians with actionable data for early intervention. "Our new cardiopulmonary system is designed to fit seamlessly into the workflow of care and perform a variety of physiological measurements that allow care teams to make early clinical decisions," said Dr. Gopinathan.

ADI's Sensinel CPM System is now commercially available, offering a transformative solution for managing chronic conditions like heart failure and enhancing patient outcomes.